Study #2022-0842
A phase I/II open-label study to assess safety, tolerability and preliminary efficacy of the CLEVER-1 Antibody Bexmarilimab in combination with standard of care therapy in patients with Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
Bexmarilimab, Azacitidine, Venetoclax
Description
This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
Study phase:
Physician name:
Naval Daver
Department:
Leukemia
For general questions about clinical trials:
1-855-922-5134
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.